Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Metabolic syndrome components were associated with higher odds of sleep apnea symptoms among adolescents and young adults in the US.

Given the high prevalence of substance use disorders, we are also carefully screening for such symptoms, as the impact of ...

Abstract: A large number of obstructive sleep apnea (OSA) cases are under-diagnosed due unavailability, inconvenience or expense of sleep labs. Hence, an automated detection by applying computational ...